Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun US Chief Gandhi Settles Insider Trading Case

Executive Summary

Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of  the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.

You may also be interested in...



India Corporate Governance Practices – Will Pharma Walk The Gandhian Path?

As Sun Pharma firefights allegations of corporate governance lapses, Scrip speaks to multiple experts on how they view the governance landscape across Pharma Inc in India and also some key sticking points.

Sun denies Ranbaxy deal insider trading suggestions

Sun Pharma had moved swiftly to clarify that it has not violated insider trading rules, amid suggestions that India's markets regulator may consider a preliminary probe into the significant spike in Ranbaxy's shares on local bourses ahead of its acquisition by Sun.

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

GB140250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel